News & Media > SARS-CoV-2 vaccine advice for adults living with HIV: British HIV Association (BHIVA) & Terrence Higgins Trust (THT) guidance

SARS-CoV-2 vaccine advice for adults living with HIV: British HIV Association (BHIVA) & Terrence Higgins Trust (THT) guidance

This guidance was updated on 11 January 2021; click here to see the latest version


Wednesday 9 December 2020

Introduction

The UK was the first country to approve the use of a SARS-CoV-2 vaccine, Pfizer’s BioNTech COVID-19 vaccine, to prevent COVID-19 disease on 2nd December 2020.

The Medicines and Healthcare Regulatory Authority (MHRA) is a branch of the Department of Health and Social Care, regulates medicines in the UK and monitors safety once a product has been approved. The MHRA, with advice from the independent advisory body, the Commission on Human Medicines, make recommendations for approval of medicines in the UK.

The Joint Committee on Vaccination and Immunisation (JCVI) is an independent group of experts who advise the Government health departments in the four UK nations on immunisations and the prevention of infectious disease. The JCVI advise how best to get vaccines to the public and where further research or surveillance may be required; their priority for the first COVID-19 vaccination phase is to reduce mortality and serious disease, and protect the NHS and social care system.


Are the vaccines live?

No, none of the SARS-CoV-2 vaccines in development are live. Of the two most advanced vaccines:

  • Pfizer’s BioNTech vaccine is a synthetic mRNA vaccine

  • AstraZeneca’s ChAdOx1 vaccine is replication-defective chimpanzee adenovirus-vectored vaccine expressing a sequence of the SARS-CoV-2 gene


Who will be prioritised to get the vaccine early?

The JCVI has recommended nine priority groups based on age, residency in care institutions, occupation and the presence of medical conditions or treatments that suppress the immune system. These priority groups are estimated to include 99% of the people at risk of dying from COVID-19 and are outlined in the Green Book chapter on COVID-19: https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a

The JCVI has recommended nine priority groups

Priority group 4: Clinically Extremely Vulnerable


Priority group 6: people with underlying health conditions which put them at higher risk of serious disease and mortality

These conditions are outlined in the Green Book and include all people with HIV.


Is the vaccine safe for people with HIV?

Data on SARS-CoV-2 vaccines in people with HIV is limited, but based on their safety profiles to date, and the nature of the vaccines, there is no reason for additional concern at present. People with HIV can produce weaker responses to some vaccines; we do not yet know if this applies to SARS-CoV-2 vaccines but will monitor this carefully and update this guidance accordingly.


Further information

Further information for health care professionals about the Pfizer vaccine, pending formal MHRA approval, can be accessed here: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/940565/Information_for_Healthcare_Professionals_on_Pfizer_BioNTech_COVID-19_vaccine.pdf


Notes: Safety data will be produced rapidly as the vaccine is rolled out. Please see MHRA website for the latest information.


For further information, please contact bhiva@bhiva.org or for media enquiries, please contact Jo Josh at jo@commsbiz.com or +44 (0)7306 391875.